Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System.
-
アブストラクト The increasing utilization of cannabis products combined with lack of data regarding potential cannabis-prescription drug interactions is concerning. This study aimed to review published case reports and FDA Adverse Event Reporting System (FAERS) spontaneous reports to assess cannabis-drug interactions in persons aged 18 and over. A literature search identified 20 case reports that were each assessed for drug interaction causality using the Drug Interaction Probability Scale. Data collected from the FAERS revealed a greater proportion of reports mentioning serious outcomes, including death, when cannabis was used concomitantly with controlled substances compared to noncontrolled substances. Fisher's exact test showed a statistically significant difference between the controlled and noncontrolled groups (p = 0.043). Overall, these findings emphasize the need for additional research and vigilant monitoring of cannabis use when combined with other medications. ジャーナル名 Pharmacology research & perspectives Pubmed追加日 2024/12/25 投稿者 Chapin, Maryann R; Kane-Gill, Sandra L; Li, Xiaotong; Abanyie, Kojo; Taneja, Sanya B; Egbert, Susan; Paine, Mary F; Boyce, Richard D 組織名 Department of Pharmacy & Therapeutics, School of Pharmacy, University of;Pittsburgh, Pittsburgh, Pennsylvania, USA.;Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh,;Pennsylvania, USA.;Intelligent Systems Program, University of Pittsburgh, Pittsburgh, Pennsylvania,;USA.;Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada.;Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical;Sciences, Washington State University, Spokane, Washington, USA. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/39719832/ -
お問合わせ
検索
メルマガ登録
